Impacting the pathophysiology of malabsorption induced by Myosin Vb inactivating mutations
影响肌球蛋白 Vb 失活突变引起的吸收不良的病理生理学
基本信息
- 批准号:10365488
- 负责人:
- 金额:$ 38.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-25 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgonistAlkaline PhosphataseApicalBiological AssayBody Weight decreasedBrush BorderBypassCell Differentiation processCell LineageCell physiologyCellsCharacteristicsChildChildhoodChloridesDataDefectDiarrheaDiseaseElectrophysiology (science)Energy Metabolism PathwayEnterocytesEpithelialEpithelial CellsExperimental ModelsFamily suidaeFunctional disorderGenetic EngineeringGlucoseImageIn SituInjectionsIntestinal MucosaIntestinesKnock-outKnockout MiceLifeLipidsLiquid substanceLysophosphatidic Acid ReceptorsMalabsorption SyndromesMass Spectrum AnalysisMediatingMembrane ProteinsMetabolicMetabolic PathwayMetabolismMicrovillus inclusion diseaseModelingMotorMusMutationMyosin ATPaseNavajoNonmuscle Myosin Type IIANutrientOligo-1,6-GlucosidaseOrganoidsPaneth CellsPathway interactionsPatientsPatternPharmaceutical PreparationsPhospholipidsPoint MutationPopulationProteinsProtonsReceptor ActivationReportingSensorySignal TransductionSodiumSolubilityStructureSucroseSymptomsTechniquesTherapeuticTissuesTo specifyTransgenic MiceTransplantationVillusWaterabsorptionapical membranecellular microvillusdiarrheal diseasedosagedrug efficacyfatty acid oxidationgastrointestinal transplantationimprovedin vivointestinal cryptintestinal epitheliumketogenesislipid biosynthesislysophosphatidic acidmetabolomicsmouse modelmutantnutrient absorptionnutritionpolarized cellprotein transportself-renewalstemstem cell functionstem cellstherapeutic targettherapy developmenttraffickingtranscriptome sequencing
项目摘要
Abstract
Myosin Vb (MYO5B) is a motor protein that is critical for cell polarization and protein trafficking towards the
apical membrane in epithelial cells. Inactivating MYO5B mutations cause the congenital diarrheal disease,
microvillus inclusion disease (MVID), which leads to life-threatening diarrhea and malabsorption. In MYO5B
knockout mice, as well as in MVID patient intestines, apical proteins that mediate nutrient and water absorption
are mis-localized away from the brush border of intestinal epithelial cells. We recently found that a bioactive
phospholipid, lysophosphatidic acid (LPA), can promote microvillus maturation and normalize localization of
sodium-dependent glucose cotransporter 1 and sodium/proton exchanger (NHE)3, important apical sodium
transporters that promote water absorption, both in MYO5B knockout tissues and organoids. However, LPA
injection did not significantly improve body weight loss induced by conditional MYO5B knockout in mice. We
hypothesize that the low solubility and fast degradation of natural LPA limit delivery of a sufficient dosage to
ameliorate intestinal deficits in vivo, and that potent LPA receptor (LPAR) agonists are more efficient. We
synthesized selective agonists for LPAR1 and LPAR5. Our preliminary data indicate that the LPAR5 agonist,
Compound-1, significantly improved villus/crypt ratios and apical NHE3 localization in MYO5B knockout mice.
We anticipate that LPAR5 activation can stimulate enterocyte differentiation and apical membrane trafficking
that bypass the blockades induced by loss of MYO5B function, leading to improved microvillus and villus
structure, nutrient transporter localization, and nutrient absorption. First, we will evaluate the therapeutic
potential of LPAR5 agonist treatment on epithelial cell function in mice with inactivating MYO5B mutations. In
addition to MYO5B deletion models, we will evaluate the effects of Compound-1 on mice with a G519R point
mutation in MYO5B (identified in a severe MVID patient). In addition to the mis-trafficking of nutrient
transporters, we have found that functional MYO5B loss induces cell lineage differentiation deficits. MYO5B
knockout mice show increased numbers of Paneth cells along with hyperproliferation, while sensory tuft cells
are reduced by 80%. LPA treatment reversed the tuft cell reductions in MYO5B knockout mice, suggesting that
LPA signaling enhances proper cell differentiation. Second, to specify MYO5B function in progenitor cells,
Myo5bflox/flox mice will be crossed with Lrig1-CreERT2 mice and the effects on epithelial proliferation and
differentiation will be characterized with or without Compound-1 treatment. Third, to understand the
mechanisms that underlie the hyperproliferation and differentiation deficits, we will determine the alterations in
cellular metabolic pathways in MYO5B-deficient mouse intestine before and after LPAR5 activation. We will
utilize imaging mass spectrometry techniques to provide spatial and quantitative metabolomics data in situ.
The use of potent and soluble LPAR5 agonist as a treatment for malabsorption may provide a safer alternative
to transplantation or life-long TPN in children with MVID as well as general diarrheal symptom.
摘要
肌球蛋白Vb(MYO 5 B)是一种马达蛋白,其对于细胞极化和蛋白质运输朝向肌球蛋白B是关键的。
上皮细胞的顶膜。MYO 5 B突变失活导致先天性睾丸炎,
微绒毛包涵体病(MVID),其导致危及生命的腹泻和吸收不良。在MYO 5 B中
敲除小鼠以及MVID患者肠道中,介导营养和水吸收的顶端蛋白质
被错误地定位在远离肠上皮细胞刷状缘的位置。我们最近发现,
磷脂,溶血磷脂酸(LPA),可以促进微绒毛成熟和正常化的定位,
钠依赖性葡萄糖协同转运蛋白1和钠/质子交换器(NHE)3,重要的顶端钠
在MYO 5 B敲除组织和类器官中促进水吸收的转运蛋白。然而,LPA
注射没有显著改善小鼠中由条件MYO 5 B敲除诱导的体重减轻。我们
假设天然LPA的低溶解度和快速降解限制了足够剂量的递送,
改善体内肠道缺陷,并且有效的LPA受体(LPAR)激动剂更有效。我们
合成了LPAR 1和LPAR 5的选择性激动剂。我们的初步数据表明,LPAR 5激动剂,
化合物-1显著改善MYO 5 B敲除小鼠中的绒毛/隐窝比率和顶端NHE 3定位。
我们预期,LPAR 5的激活可以刺激肠上皮细胞的分化和顶膜运输
绕过MYO 5 B功能丧失引起的阻塞,导致微绒毛和绒毛改善,
结构、营养转运蛋白定位和营养吸收。首先,我们将评估治疗
在具有失活MYO 5 B突变的小鼠中,LPAR 5激动剂治疗对上皮细胞功能的潜力。在
除了MYO 5 B缺失模型之外,我们将评估化合物-1对具有G519 R点的小鼠的作用
MYO 5 B突变(在重度MVID患者中发现)。除了营养物质的错误运输
在MYO 5 B转运蛋白中,我们发现功能性MYO 5 B缺失诱导细胞谱系分化缺陷。MYO5B
敲除小鼠显示潘氏细胞数量增加,沿着过度增殖,而感觉丛细胞
减少了80%。LPA治疗逆转了MYO 5 B基因敲除小鼠中簇状细胞的减少,这表明
LPA信号传导增强适当的细胞分化。第二,为了确定MYO 5 B在祖细胞中的功能,
Myo 5 bflox/flox小鼠将与Lrig 1-CreERT 2小鼠杂交,并观察对上皮细胞增殖和
分化将在有或没有化合物-1处理的情况下表征。第三,了解
机制的基础上过度增殖和分化缺陷,我们将确定的变化,
在LPAR 5活化之前和之后MYO 5 B缺陷小鼠肠中的细胞代谢途径。我们将
利用成像质谱技术提供空间和定量代谢组学数据。
使用强效可溶性LPAR 5激动剂治疗吸收不良可能提供更安全的替代方案
对MVID伴全身消化道症状的患儿进行移植或终身TPN治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Izumi Kaji其他文献
Izumi Kaji的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Izumi Kaji', 18)}}的其他基金
Impacting the pathophysiology of malabsorption induced by Myosin Vb inactivating mutations
影响肌球蛋白 Vb 失活突变引起的吸收不良的病理生理学
- 批准号:
10673724 - 财政年份:2021
- 资助金额:
$ 38.06万 - 项目类别:
Impacting the pathophysiology of malabsorption induced by Myosin Vb inactivating mutations
影响肌球蛋白 Vb 失活突变引起的吸收不良的病理生理学
- 批准号:
10494249 - 财政年份:2021
- 资助金额:
$ 38.06万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 38.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 38.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 38.06万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 38.06万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 38.06万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 38.06万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 38.06万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 38.06万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 38.06万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 38.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)